Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARDX

Ardelyx Inc

Oct 24 • 04:00PM ET

5.04

-0.02 -0.40 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX NBIX ENTA BMRN EXEL AKTX SRPT IRWD

| Held by: VTI IWM XBI VXF IWO VTWO SCHA VHT FYC FYX

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.24	Insider Own	3.96%	Shs Outstand	240.77M	Perf Week	0.20%
Market Cap	1.21B	Forward P/E	132.91	EPS next Y	0.04	Insider Trans	6.60%	Shs Float	231.44M	Perf Month	-15.44%
Enterprise Value	1.18B	PEG	-	EPS next Q	-0.06	Inst Own	69.80%	Short Float	8.42%	Perf Quarter	17.76%
Income	-56.39M	P/S	3.15	EPS this Y	-94.16%	Inst Trans	1.26%	Short Ratio	5.35	Perf Half Y	-4.18%
Sales	386.15M	P/B	8.70	EPS next Y	111.49%	ROA	-13.92%	Short Interest	19.48M	Perf YTD	-0.59%
Book/sh	0.58	P/C	5.09	EPS next 5Y	-	ROE	-39.36%	52W High	6.78 -25.66%	Perf Year	-12.80%
Cash/sh	0.99	P/FCF	-	EPS past 3/5Y	52.14% 35.34%	ROIC	-16.34%	52W Low	3.21 57.01%	Perf 3Y	231.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	220.89% 129.14%	Gross Margin	84.21%	Volatility	3.91% 4.04%	Perf 5Y	-11.89%
Dividend TTM	-	EV/Sales	3.06	EPS Y/Y TTM	15.24%	Oper. Margin	-10.46%	ATR (14)	0.20	Perf 10Y	-74.06%
Dividend Ex-Date	-	Quick Ratio	4.03	Sales Y/Y TTM	83.88%	Profit Margin	-14.60%	RSI (14)	36.97	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	4.30	EPS Q/Q	-13.25%	SMA20	-2.43%	Beta	0.66	Target Price	11.36
Payout	-	Debt/Eq	1.48	Sales Q/Q	33.38%	SMA50	-13.47%	Rel Volume	0.63	Prev Close	5.06
Employees	395	LT Debt/Eq	1.47	Earnings	Oct 30 AMC	SMA200	1.08%	Avg Volume	3.64M	Price	5.04
IPO	Jun 19, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	39.26% 20.45%	Trades		Volume	2,287,969	Change	-0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Resumed	Raymond James	Strong Buy	$14
Jun-18-25	Resumed	H.C. Wainwright	Buy	$10
May-02-25	Downgrade	Raymond James	Strong Buy → Outperform	$11
Mar-07-25	Resumed	Ladenburg Thalmann	Buy
Mar-04-25	Initiated	BTIG Research	Buy	$14
Nov-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$11 → $5.50
Jul-02-24	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $7
Apr-05-24	Initiated	Leerink Partners	Outperform	$14
Dec-18-23	Initiated	Raymond James	Strong Buy	$12
Sep-07-23	Initiated	H.C. Wainwright	Buy	$9
Aug-25-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$5 → $10
Mar-03-23	Upgrade	Wedbush	Neutral → Outperform	$3 → $6
Nov-17-22	Upgrade	Piper Sandler	Neutral → Overweight	$3 → $8
May-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$7 → $1
Dec-01-21	Upgrade	Ladenburg Thalmann	Neutral → Buy	$6
Oct-14-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jul-21-21	Downgrade	Jefferies	Buy → Hold	$11 → $2
Jul-20-21	Downgrade	Wedbush	Outperform → Neutral	$3
Jul-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$14 → $4
Mar-23-21	Initiated	Wedbush	Outperform	$14

Show Previous Ratings

Oct-21-25 08:00AM	Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week (GlobeNewswire)
Oct-16-25 07:30AM	2 Overlooked Stocks to Snap Up in 2025 (Barchart)
Oct-13-25 08:35AM	Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025 (GlobeNewswire)
08:30AM	Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer (GlobeNewswire)
Sep-24-25 07:30AM	Is This Under-$10 Stock the Next Big Biotech Winner? (Barchart)
05:10AM	Loading…
Aug-29-25 05:10AM	Ardelyx, Inc. (ARDX) Strengthens Global Reach with Kyowa Kirin Deal (Insider Monkey)
Aug-25-25 08:00AM	Ardelyx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 08:00AM	Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire)
Aug-05-25 03:04AM	Ardelyx Inc (ARDX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com) +16.86%
Aug-04-25 06:30PM	Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:30PM	Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Ardelyx: Q2 Earnings Snapshot (Associated Press Finance)
04:08PM	Ardelyx Announces Changes to the Executive Leadership Team (GlobeNewswire)
04:01PM	Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
10:01AM	Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) (Insider Monkey)
10:00AM	Loading…
Jul-29-25 10:00AM	Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-28-25 10:00AM	Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline (Zacks)
Jul-23-25 11:25AM	Ardelyx (ARDX) Announced New data for IBSRELA (Insider Monkey)
Jul-21-25 08:00AM	Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire)
Jul-15-25 07:30AM	This Small-Cap Stock Could 10x by 2030, But Its Not for the Faint of Heart (Barchart)
Jul-07-25 09:10AM	Jefferies Maintains a Buy Rating on Ardelyx (ARDX) With an $8 Price Target (Insider Monkey)
Jul-01-25 04:00AM	A biopharma doubles down on diversity goals through a newly created position (Pharma Voice)
04:00AM	A biopharma bolsters patient centricity and trial diversity goals through newly created role (Pharma Voice)
Jun-29-25 03:00AM	Two Beaten-Down Biotech Stocks See Big Insider Buys (Barrons.com)
Jun-25-25 01:01PM	H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy (Insider Monkey)
Jun-24-25 03:51PM	Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT (Insider Monkey)
Jun-02-25 04:05PM	Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer (GlobeNewswire)
May-21-25 08:00AM	Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-06-25 08:01AM	Ardelyx Presents Data Supporting IBSRELA (tenapanor) at Digestive Disease Week 2025 Conference (GlobeNewswire) +5.76%
May-02-25 10:07AM	Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty (Seeking Alpha) -24.50%
07:30AM	Loading…
07:30AM	Q1 2025 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Ardelyx Inc (ARDX) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amid Market Challenges (GuruFocus.com)
May-01-25 10:06PM	Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:29PM	Ardelyx: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-25 08:00AM	Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Apr-24-25 08:01AM	Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference (GlobeNewswire)
Apr-17-25 08:00AM	Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 (GlobeNewswire)
Apr-16-25 11:21AM	Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-10-25 04:02PM	Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings (GlobeNewswire) -5.56%
Mar-31-25 04:03PM	Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH (tenapanor) at the National Kidney Foundation Spring Clinical Meetings (GlobeNewswire)
Mar-13-25 08:02AM	Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award (GlobeNewswire)
Feb-26-25 07:00AM	Tenapanor Approved in China for Hyperphosphatemia (GlobeNewswire)
Feb-25-25 04:15PM	Ardelyx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-25 02:05AM	Ardelyx Inc (ARDX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Challenges (GuruFocus.com) -11.54%
Feb-20-25 11:51PM	Q4 2024 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) -10.06%
09:30AM	Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:45AM	Ardelyx (ARDX) Meets Q4 Earnings Estimates (Zacks)
07:52AM	Ardelyx: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-19-25 08:01AM	Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-13-25 10:01AM	Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-30-25 04:30PM	Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 (GlobeNewswire)
Jan-23-25 01:41PM	Chairman David Mott Bets $1M on Ardelyx--Is This Biotech Stock Set to Skyrocket? (GuruFocus.com) +9.11%
Jan-14-25 09:07AM	Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last? (Zacks)
Jan-13-25 08:03AM	Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities (GlobeNewswire) +15.98%
Jan-06-25 08:00AM	Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:41PM	Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Nov-20-24 08:00AM	Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 12:31PM	Ardelyx Responds to District Court Decision Granting Motion to Dismiss (GlobeNewswire) -20.53%
Nov-05-24 08:00AM	Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-01-24 10:04AM	Q3 2024 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
03:18AM	Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ... (GuruFocus.com)
Oct-31-24 05:30PM	Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q3 (Zacks)
04:22PM	Ardelyx: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 04:05PM	Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting (GlobeNewswire)
Oct-24-24 04:05PM	Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH (tenapanor) at the American Society of Nephrology's Kidney Week (GlobeNewswire) +5.02%
10:01AM	Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 04:05PM	Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community (GlobeNewswire)
Oct-21-24 04:05PM	Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community (GlobeNewswire)
Oct-18-24 09:55AM	Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher (Zacks)
Oct-17-24 08:00AM	Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week (GlobeNewswire)
Oct-11-24 09:00AM	Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CXM (PR Newswire)
Oct-09-24 03:53PM	Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges (GuruFocus.com)
12:46PM	Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights ARDX (GlobeNewswire)
08:05AM	Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology (GlobeNewswire)
Oct-07-24 09:55AM	Wall Street Analysts Think Ardelyx (ARDX) Could Surge 65.4%: Read This Before Placing a Bet (Zacks) -10.12%
Oct-03-24 05:45AM	Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ARDX (PR Newswire)
Sep-30-24 01:02PM	Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights ARDX (GlobeNewswire)
Sep-10-24 05:45AM	Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX (PR Newswire)
Sep-06-24 05:45AM	Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX (PR Newswire)
Sep-05-24 08:00AM	Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-28-24 12:43PM	Ardelyx, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights ARDX (GlobeNewswire)
Aug-08-24 08:00AM	Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer (GlobeNewswire) +5.77%
Aug-01-24 07:30PM	Here's What Key Metrics Tell Us About Ardelyx (ARDX) Q2 Earnings (Zacks) +10.00%
05:45PM	Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Ardelyx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 08:02AM	Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH (tenapanor) Clinical Trials in Current Medical Research and Opinion (GlobeNewswire)
Jul-25-24 10:01AM	Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-18-24 02:53PM	Ardelyx sues CMS over revamped kidney disease drug payment bundle (Pharmaceutical Technology)
08:00AM	Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jul-17-24 05:10PM	Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines (GlobeNewswire) -7.41%
Jul-02-24 07:00AM	To Preserve Patient Access to XPHOZAH , Ardelyx Chooses Not to File for TDAPA (GlobeNewswire) -30.25%
Jun-28-24 08:17AM	Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines (GlobeNewswire) +14.00%

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Laura A	Chief Patient Officer	Aug 26 '25	Option Exercise	0.99	50,000	49,500	446,322	Aug 28 07:30 PM
Williams Laura A	Chief Patient Officer	Aug 26 '25	Sale	6.12	80,000	489,680	366,322	Aug 28 07:30 PM
Kelliher Mike	Chief Business Officer	Aug 21 '25	Sale	5.93	5,417	32,132	276,741	Aug 28 07:29 PM
LAURA A WILLIAMS	Officer	Aug 26 '25	Proposed Sale	6.06	80,000	484,800		Aug 26 04:29 PM
Williams Laura A	Chief Patient Officer	Aug 21 '25	Sale	5.93	6,261	37,138	396,322	Aug 25 09:13 PM
Renz Justin A	Chief Financial Officer	Aug 21 '25	Sale	5.93	7,037	41,741	409,052	Aug 25 09:12 PM
RAAB MICHAEL	President & CEO	Aug 21 '25	Sale	5.93	45,687	271,002	1,502,250	Aug 25 09:08 PM
GRAMMER ELIZABETH A	See Remarks	Aug 21 '25	Sale	5.93	5,841	34,647	305,890	Aug 25 09:03 PM
Foster Eric Duane	Chief Commercial Officer	Aug 21 '25	Sale	5.93	15,308	90,802	301,498	Aug 25 09:02 PM
MOTT DAVID M	Director	Jun 16 '25	Buy	3.63	200,000	725,880	2,896,871	Jun 18 09:28 PM
MOTT DAVID M	Director	Jun 09 '25	Buy	3.69	200,000	737,260	2,696,871	Jun 11 09:40 PM
Williams Laura A	Chief Medical Officer	May 20 '25	Sale	4.08	6,421	26,207	402,583	May 22 09:55 PM
Renz Justin A	Chief Financial Officer	May 20 '25	Sale	4.08	7,218	29,460	416,089	May 22 09:53 PM
RAAB MICHAEL	President & CEO	May 20 '25	Sale	4.08	46,817	191,079	1,547,937	May 22 09:52 PM
Kelliher Mike	See Remarks	May 20 '25	Sale	4.08	14,522	59,270	282,158	May 22 09:51 PM
GRAMMER ELIZABETH A	See Remarks	May 20 '25	Sale	4.08	5,992	24,456	311,731	May 22 09:50 PM
Foster Eric Duane	Chief Commercial Officer	May 20 '25	Sale	4.08	2,507	10,232	316,806	May 22 09:49 PM
MOTT DAVID M	Director	May 15 '25	Buy	3.29	100,000	329,120	2,496,871	May 19 05:02 PM
MOTT DAVID M	Director	May 02 '25	Buy	4.22	381,377	1,610,936	2,396,871	May 05 08:22 PM
RAAB MICHAEL	President & CEO	May 02 '25	Option Exercise	0.99	20,833	20,625	1,636,420	May 05 08:14 PM
RAAB MICHAEL	President & CEO	May 02 '25	Sale	4.25	41,666	177,168	1,594,754	May 05 08:14 PM
MICHAEL RAAB	Director	May 02 '25	Proposed Sale	5.47	125,000	683,750		May 02 04:22 PM
RAAB MICHAEL	President & CEO	Apr 04 '25	Option Exercise	0.99	20,833	20,625	1,657,253	Apr 08 07:24 PM
RAAB MICHAEL	President & CEO	Apr 04 '25	Sale	4.59	41,666	191,151	1,615,587	Apr 08 07:24 PM
Rosenbaum David P.	Officer	Mar 17 '25	Proposed Sale	5.47	44,330	242,559		Mar 17 05:40 PM
RAAB MICHAEL	President & CEO	Mar 07 '25	Option Exercise	0.99	20,834	20,626	1,676,806	Mar 07 07:25 PM
RAAB MICHAEL	President & CEO	Mar 07 '25	Sale	5.36	41,668	223,199	1,635,138	Mar 07 07:25 PM
MOTT DAVID M	Director	Feb 24 '25	Buy	5.00	77,729	388,738	2,015,494	Feb 26 07:21 PM
Williams Laura A	Chief Medical Officer	Feb 20 '25	Sale	5.62	4,941	27,783	303,804	Feb 21 06:56 PM
Renz Justin A	Chief Financial Officer	Feb 20 '25	Sale	5.62	5,171	29,077	285,968	Feb 21 06:55 PM
RAAB MICHAEL	President & CEO	Feb 20 '25	Sale	5.62	22,964	129,124	1,085,755	Feb 21 06:54 PM
GRAMMER ELIZABETH A	See Remarks	Feb 20 '25	Sale	5.62	4,291	24,128	181,043	Feb 21 06:53 PM
Blanks Robert	Officer	Feb 12 '25	Proposed Sale	5.46	75,000	409,765		Feb 12 05:58 PM
RAAB MICHAEL	President & CEO	Jan 31 '25	Option Exercise	0.99	20,833	20,625	1,150,385	Jan 31 08:16 PM
RAAB MICHAEL	President & CEO	Jan 31 '25	Sale	5.36	41,666	223,355	1,108,719	Jan 31 08:16 PM
MOTT DAVID M	Director	Jan 21 '25	Buy	4.99	199,000	992,672	1,937,765	Jan 22 05:25 PM
Rodgers Richard J	Director	Jan 16 '25	Option Exercise	0.55	100,000	55,000	350,524	Jan 17 04:44 PM
DAVID P ROSENBAUM	Officer	Jan 16 '25	Proposed Sale	5.35	110,000	588,500		Jan 16 04:32 PM
RAAB MICHAEL	President & CEO	Jan 07 '25	Option Exercise	0.99	20,833	20,625	1,171,218	Jan 10 04:58 PM
RAAB MICHAEL	President & CEO	Jan 07 '25	Sale	5.31	41,666	221,309	1,129,552	Jan 10 04:58 PM
MICHAEL RAAB	Director	Jan 07 '25	Proposed Sale	5.00	166,666	833,330		Jan 07 04:18 PM
MOTT DAVID M	Director	Dec 26 '24	Option Exercise	0.55	100,000	55,000	1,738,765	Dec 27 05:57 PM
MOTT DAVID M	Director	Dec 19 '24	Buy	4.67	213,300	996,580	1,638,765	Dec 23 05:59 PM
RAAB MICHAEL	President & CEO	Dec 10 '24	Option Exercise	0.99	25,000	24,750	1,175,385	Dec 12 07:02 PM
RAAB MICHAEL	President & CEO	Dec 10 '24	Sale	5.26	25,000	131,620	1,150,385	Dec 12 07:02 PM
MICHAEL G. RAAB	Officer	Dec 10 '24	Proposed Sale	5.26	25,000	131,618		Dec 10 04:09 PM
RAAB MICHAEL	President & CEO	Nov 25 '24	Sale	5.38	25,000	134,482	1,150,385	Nov 27 08:15 PM
MICHAEL G. RAAB	Officer	Nov 25 '24	Proposed Sale	5.38	25,000	134,480		Nov 25 04:15 PM
Williams Laura A	Chief Medical Officer	Nov 20 '24	Sale	4.79	7,366	35,316	308,745	Nov 22 06:37 PM
Rosenbaum David P.	Chief Development Officer	Nov 20 '24	Sale	4.79	4,941	23,690	297,005	Nov 22 06:34 PM
Rosenbaum David P.	Chief Development Officer	Nov 20 '24	Sale	4.79	2,243	10,754	151,373	Nov 22 06:34 PM
Renz Justin A	Chief Financial Officer	Nov 20 '24	Sale	4.79	5,260	25,219	291,139	Nov 22 06:33 PM
RAAB MICHAEL	President & CEO	Nov 20 '24	Sale	4.79	31,980	153,328	1,175,385	Nov 22 06:31 PM
GRAMMER ELIZABETH A	See Remarks	Nov 20 '24	Sale	4.79	7,046	33,782	185,334	Nov 22 06:24 PM
Blanks Robert	See Remarks	Nov 20 '24	Sale	4.79	4,941	23,690	314,421	Nov 22 06:22 PM
MOTT DAVID M	Director	Nov 13 '24	Buy	4.62	215,868	996,598	1,425,465	Nov 14 04:26 PM
RAAB MICHAEL	President & CEO	Nov 11 '24	Sale	4.90	2,743	13,441	1,207,365	Nov 12 05:00 PM
MICHAEL G. RAAB	Officer	Nov 11 '24	Proposed Sale	4.90	2,743	13,441		Nov 12 11:44 AM
Rosenbaum David P.	Chief Development Officer	Nov 06 '24	Option Exercise	2.32	27,171	63,037	180,787	Nov 08 06:00 PM
Rosenbaum David P.	Chief Development Officer	Nov 06 '24	Sale	6.10	27,171	165,743	153,616	Nov 08 06:00 PM
Rosenbaum David P.	Chief Development Officer	Nov 04 '24	Option Exercise	2.32	27,172	63,039	180,788	Nov 06 05:59 PM
Rosenbaum David P.	Chief Development Officer	Nov 04 '24	Sale	5.95	27,172	161,673	153,616	Nov 06 05:59 PM
RAAB MICHAEL	President & CEO	Oct 28 '24	Option Exercise	0.99	25,000	24,750	1,235,108	Oct 31 08:24 AM
RAAB MICHAEL	President & CEO	Oct 28 '24	Sale	5.91	25,000	147,740	1,210,108	Oct 31 08:24 AM
MICHAEL G. RAAB	Officer	Oct 28 '24	Proposed Sale	5.91	25,000	147,740		Oct 28 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARDX

Ardelyx Inc

Upgrade your FINVIZ experience